Iressa does not improve survival for patients with the most common form of lung cancer, The Lancet
2nd Nov 2005, 18:36 GMT
A randomised trial in this week's issue of The Lancet has found that the lung cancer drug Iressa (gefitinib) is not associated with a significant improvement in survival for people with non-small cell lung cancer (NSCLC). However, the study did find some evidence of benefit among never-smokers and patients of Asian origin... click link for more info.
Iressa does not improve survival for patients with the most common form of lung cancer, The Lancet related news:
- First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer — News-Medical News Feed
- Dentists could help detect lung cancer - Inner cheek cells can be used — Medical News Today RSS/XML Feed
- Cheek cells can detect lung cancer, says study — KeralaNext: Health
- Lung-Sparing Treatment For Cancer Proving Effective — Medical News Today RSS/XML Feed
- Stereotactic body radiation therapy safe and effective way to treat early stage lung cancer in medically inoperable patients — News-Medical News Feed
- Gemcitabine and capecitabine improved overall survival in patients with advanced pancreatic cancer — EurekAlert! - Breaking News
- New Technology Boosts Lung Cancer Treatment (HealthDay) — Yahoo! News: Health News
- New treatments improve lymphoma survival — Reuters: Health
- Focus on lung cancer: How to prevent and treat it — KeralaNext: Science
- Women with lung cancer tend to live longer than men, regardless of treatment — Medical News Today RSS/XML Feed
Latest news from Medical News Today RSS/XML Feed:
- Biotech Industry Welcomes WHO Initiative On Naming Of Biologicals Including Biosimilar Medicines
- Common Cause Of Heart Disease, Diabetes May Be Treatable With Malaria Drug
- Two Nerve Cells In Direct Contact
- Value Of 'Helper' Compound In Treating Some Leukemias
- Internists Take Home Several National Awards At AAMC Annual Meeting
- Most Canadian Med School Grads Lack Basic Surgical Skills
- ACP's Electronic Medical Resource Ranked No. 1 Evidence-based Tool By MLA's South Central Chapter
- University Of Illinois Scientist Helping Processors Keep E. Coli Out Of Meat
- American Thoracic Society Publishes New Statement On Hepatotoxicity Of Antituberculosis Therapy
- Neural Networking Nanotubes